Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Geraldine Jeudy
Based on 4 articles published since 2008
||||

Between 2008 and 2019, G. Jeudy wrote the following 4 articles about Melanoma.
 
+ Citations + Abstracts
1 Guideline [Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie]. 2018

Guillot, B / Charles, J / Jeudy, G / Cupissol, D / Dupuy, A / Dutriaux, C / Gangloff, D / Magne, N / Mirabel, X / M'Sadek, A / Pracht, M / Sichel, C / Do Outeiro, G. ·Département de dermatologie, hôpital Saint-Éloi, CHU de Montpellier, 34295 Montpellier, France. Electronic address: b-guillot@chu-montpellier.fr. · CHU de Grenoble, 38700 Grenoble, France. · CHU de Dijon, 21000 Dijon, France. · Institut du Cancer de Montpellier, 34298 Montpellier, France. · CHU de Rennes, 35000 Rennes, France. · CHU de Bordeaux, 33000 Bordeaux, France. · Institut universitaire du cancer de Toulouse, 31100 Toulouse, France. · Institut de cancérologie de la Loire, 42270 Saint-Priest-en-Jarez, France. · Centre Oscar-Lambret, 59000 Lille, France. · Centre Eugène-Marquis, 35000 Rennes, France. · 13470 Carnoux en Provence, France. · Institut national du cancer de Boulogne-Billancourt, 92100 Boulogne-Billancourt, France. ·Ann Dermatol Venereol · Pubmed #29703640.

ABSTRACT: -- No abstract --

2 Article Prospective study of the evolution of blood lymphoid immune parameters during dacarbazine chemotherapy in metastatic and locally advanced melanoma patients. 2014

Mignot, Grégoire / Hervieu, Alice / Vabres, Pierre / Dalac, Sophie / Jeudy, Geraldine / Bel, Blandine / Apetoh, Lionel / Ghiringhelli, François. ·INSERM, UMR866, Dijon, France; Faculté de Médecine, Université de Bourgogne, Dijon, France. · INSERM, UMR866, Dijon, France; Faculté de Médecine, Université de Bourgogne, Dijon, France; Service de Dermatologie, Centre Hospitalier Universitaire le Bocage, Dijon, France. · Faculté de Médecine, Université de Bourgogne, Dijon, France; Service de Dermatologie, Centre Hospitalier Universitaire le Bocage, Dijon, France. · Service de Dermatologie, Centre Hospitalier Universitaire le Bocage, Dijon, France. · INSERM, UMR866, Dijon, France; Faculté de Médecine, Université de Bourgogne, Dijon, France; Oncologie médicale, Centre Georges François Leclerc, Dijon, France. ·PLoS One · Pubmed #25170840.

ABSTRACT: BACKGROUND: The importance of immune responses in the control of melanoma growth is well known. However, the implication of these antitumor immune responses in the efficacy of dacarbazine, a cytotoxic drug classically used in the treatment of melanoma, remains poorly understood in humans. METHODS: In this prospective observational study, we performed an immunomonitoring of eleven metastatic or locally advanced patients treated with dacarbazine as a first line of treatment. We assessed by flow cytometry lymphoid populations and their activation state; we also isolated NK cells to perform in vitro cytotoxicity tests. RESULTS: We found that chemotherapy induces lymphopenia and that a significantly higher numbers of naïve CD4+ T cells and lower proportion of Treg before chemotherapy are associated with disease control after dacarbazine treatment. Interestingly, NK cell cytotoxicity against dacarbazine-pretreated melanoma cells is only observed in NK cells from patients who achieved disease control. CONCLUSION: Together, our data pinpoint that some immune factors could help to predict the response of melanoma patients to dacarbazine. Future larger scale studies are warranted to test their validity as prediction markers.

3 Article Polyethylenimine-mediated in vivo gene transfer of a transmembrane superantigen fusion construct inhibits B16 murine melanoma growth. 2008

Jeudy, G / Salvadori, F / Chauffert, B / Solary, E / Vabres, P / Chluba, J. ·Inserm U866, IFR100, Faculté de Médecine, Dijon, France. ·Cancer Gene Ther · Pubmed #18617917.

ABSTRACT: Immunotherapy has been proposed as a therapeutic strategy in advanced-stage melanomas in which other therapeutic options have little effect. The Staphylococcus enterotoxin A (SEA) has been used to stimulate an antitumoral immune response but its use is hampered by severe systemic side effects. Here, we show that SEA can be targeted to melanoma cells to limit these side effects. More specifically, we used a nonviral vector, the cationic polymer, polyethylenimine (PEI), to express a transmembrane SEA fusion construct (pSEA-TM) in B16F10-induced subcutaneous melanoma in mice. The efficacy of this in vivo transfection was enhanced by concomitant infusion of epinephrine to induce local vasoconstriction. In these conditions, repeated injections of pSEA-TM/PEI complexes elicited a significant response, as evidenced by tumor growth inhibition, without systemic adverse effects. T cell infiltration of the tumors, together with positive lymphocyte proliferation tests, suggested local and systemic immune responses. Altogether, PEI-mediated targeting of SEA to melanoma tumor cells in vivo efficiently stimulates the antitumor immune response without inducing the side effects observed with systemic administration of SEA.

4 Minor Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis. 2015

Jeudy, G / Dalac-Rat, S / Bonniaud, B / Hervieu, A / Petrella, T / Collet, E / Vabres, P. ·Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France. geraldine.jeudy@chu-dijon.fr. · Service de Dermatologie, Centre Hospitalier Universitaire, 21000, Dijon, France. · Service d'Anatomie Pathologique, Centre Hospitalier Universitaire, 21000, Dijon, France. ·Br J Dermatol · Pubmed #25384395.

ABSTRACT: -- No abstract --